MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8068
+0.0618
+8.30%
After Hours: 0.8100 +0.0032 +0.40% 19:47 12/04 EST
OPEN
0.7450
PREV CLOSE
0.7450
HIGH
0.9490
LOW
0.7200
VOLUME
6.79M
TURNOVER
--
52 WEEK HIGH
1.600
52 WEEK LOW
0.2500
MARKET CAP
51.65M
P/E (TTM)
-1.6315
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DFFN: Planning for Additional Studies of TSC
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Update on COVID-19 Trial Diffusion Pharmaceuticals (NASDAQ:DFFN) is currently conducting the 100-303 COVID trial of trans sodium crocetinate (TSC) in hospitalized COVID-19 patients in Romania ( NCT04573322 ). This is primarily a safety and tolerability study of TSC when it is administered four times a day for up to
Zacks Small Cap Research · 13h ago
Is Diffusion Pharmaceuticals Inc. (DFFN) A Good Stock To Buy?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Insider Monkey · 5d ago
Diffusion Pharmaceuticals Secretary Robert William Elder Buys 15,000 Shares @ Avg Price: $0.66
-Form 4
Benzinga · 11/18 13:38
Diffusion Pharmaceuticals EPS misses by $0.01
Diffusion Pharmaceuticals (DFFN): Q3 GAAP EPS of -$0.07 misses by $0.01.Cash and cash equivalents of $21.9MPress Release
Seekingalpha · 11/12 21:35
Diffusion Pharmaceuticals Q3 EPS $(0.07) Up From $(0.60) YoY
Diffusion Pharmaceuticals (NASDAQ:DFFN) reported quarterly losses of $(0.07) per share. This is a 88.33 percent increase over losses of $(0.60) per share from the same period last year.
Benzinga · 11/12 21:04
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients
GlobeNewswire · 11/12 21:02
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 PatientsAnnounces Next Steps in Development Program for Lead Product CandidateEnded Quarter with $21.9 million in Cash and Cash EquivalentsCHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”) today reported financial results for the three and nine months ended September 30, 2020 and provided certain updates on its development program for its lead product candidate, trans sodium crocetinate (“TSC”), which is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.Third quarter results, recent developments, and anticipated next steps in the TSC development program include:Third Quarter Results & Recent Developments •Strengthened leadership team with additions and appointments to key management positions, including pharmaceutical industry veterans Jane Hollingsworth, as director, Robert Cobuzzi, Ph.D., as president and chief executive officer, and Chris Galloway, M.D., as chief medical officer, as well as Bill Elder, J.D., as general counsel.      •Ended quarter with $21.9 million in cash and cash equivalents.      •Announced dosing of first two patients in Phase 1b clinical trial evaluating TSC in hospitalized COVID-19 patients (the “100-303 COVID Trial”) with primary endpoint of evaluating safety and tolerability of TSC administered every six hours for up to 15 days, a more frequent dosing regimen than has been used in the Company’s previous clinical studies.      •As of November 11, 2020, patient enrollment continues, and no dose-limiting toxicities have been observed. Near-Term Strategy •Ongoing review of existing TSC development program with plans to modify the program and accomplish two principal strategic objectives:          •Optimize the clinical dose and dosing frequency for TSC.          •Evaluate TSC in clinical models designed to establish proof of concept for improvement in oxygenation following administration of TSC.        •Designing and initiating additional studies in effort to accomplish strategic objectives:          •Evaluating possibility of expanding 100-303 COVID Trial to include additional doses administered on the same regimen, assuming successful and timely completion of currently planned doses and final regulatory approval of pending protocol amendment to effect change.          •Designing additional clinical studies intended to evaluate (i) the effects of TSC using short-term experimental models of oxygenation with the expected primary objective of establishing proof of concept for improvement of tissue oxygen levels and certain other clinical parameters and (ii) depending on whether or not the Company decides to implement the expansion of the 100-303 COVID Trial, additional doses of TSC on a more frequent dosing regimen.        •Diffusion expects to fully fund these studies with cash-on-hand.      •Diffusion intends to provide certain additional details regarding the design of these new studies in January 2021 and to initiate the studies during the first quarter of 2021. The Company also now expects the 100-303 COVID Trial, whether or not the Company decides to implement the expansion described above, to be completed with topline data available by the end of first quarter of 2021. Other Events •Diffusion currently intends to participate in two virtual, biopharmaceutical and biotechnology industry conferences in mid-January 2021 – Biotech Showcase and the H.C. Wainwright 2021 Bioconnect Conference – and to provide its next update regarding its development program for TSC at that time.      •Launched new website design at www.diffusionpharma.com. “Hypoxia can be a serious complication of a multitude of acute and chronic disease processes in patients of all ages and represents a continued area of unmet need that spans multiple therapeutic areas. I am excited about our development plans, which we believe will clarify TSC’s mechanism of action in controlled human studies of oxygenation. We intend to use these data to inform and evaluate our further development opportunities for TSC, as well as potential patient populations and indications,” said Chris Galloway, M.D., Chief Medical Officer of Diffusion. “Diffusion has experienced a lot of changes over the past few months. While we continue to refine our vision for the Company, we are pleased with the progress we made during the third quarter and we are excited to begin implementing our plans during the coming months,” said Robert Cobuzzi, Ph.D., Chief Executive Officer of Diffusion. “We believe our near-term strategy will significantly improve the probability of development success for TSC by providing the opportunity to optimize dosing and obtain a clear clinical signal supporting the potential value of TSC’s mechanism of action across a broad range of conditions in which hypoxia remains a significant obstacle to effective treatment.”Third Quarter Financial Results Research and development (“R&D”) expenses were $3.1 million during the third quarter of 2020, compared with $1.7 million during the third quarter of 2019. A significant portion of the increase, $1.4 million, was attributable to expenses related to the initiation of the Company’s ongoing clinical trial evaluating TSC in COVID-19 patients. In addition, R&D expenses included $0.1 million related to winding down the Company’s Phase 2 stroke trial.General and administrative (“G&A”) expenses were $2.1 million during the third quarter of 2020, compared with $1.3 million during the third quarter of 2019. The increase was primarily due to a $0.2 million increase in professional fees and a $0.6 million increase in salaries, wages and stock-based compensation expenses, including non-recurring expenses related to the retirement, resignation and separation of the Company’s former Chief Executive Officer in September 2020.The Company recognized income tax benefits of $0.8 million and $0.2 million during the third quarters of 2020 and 2019, respectively. In both periods, the recognized benefit reflects the Company’s utilization of indefinite deferred tax liabilities as a source of income against indefinite lived portions of its deferred tax assets.Diffusion had cash and cash equivalents of $21.9 million as of September 30, 2020, compared with $14.2 million as of December 31, 2019, and believes its cash and cash equivalents are sufficient to fund operating expenses and capital expenditures into the fourth quarter of 2022.About Diffusion Pharmaceuticals Inc.Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. The Company’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. For more information please visit us on the web at www.diffusionpharma.com.Forward-Looking StatementsThis press release includes express and implied forward-looking statements including, without limitation, statements regarding the Company’s ongoing clinical trials and development plans for its product candidates and the Company’s financial condition, liquidity, and capital resources. By their nature, forward-looking statements involve risks and uncertainties because they relate to and depend on, among other things, events, competitive dynamics, and industry change. The Company may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, as a result of certain risks and uncertainties, known and unknown, the Company’s actual results could differ materially from any intentions, beliefs, projections, outlook, analyses, or expectations expressed herein. Particular risk and uncertainties include, among other things, those related to: the Company’s ability to design, initiate, execute, and complete its ongoing and planned studies evaluating TSC; the Company’s ability to achieve its near-term strategic objectives, in the near-term or at all; the Company’s ability to obtain additional financing; the success and timing of the Company’s clinical trials and preclinical studies, including its ability to enroll subjects in such trials and studies at anticipated rates; the Company’s ability to develop and commercialize TSC or any other product candidate; the ongoing COVID-19 pandemic; general economic, political, business, industry, and market conditions, including the recent United States (“U.S.”) presidential election; and the other factors discussed under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule or regulation, the Company undertakes no obligation to update any such statements after the date hereof. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.Investor Contact: LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.comMedia Contact: Jeffrey Freedman RooneyPartners (646) 432-0191 jfreedman@rooneyco.com(Tables to follow)  Diffusion Pharmaceuticals Inc. Consolidated Balance Sheet (unaudited)    September 30, 2020December 31, 2019 Assets   Current assets:   Cash and cash equivalents$21,910,183 $14,177,349  Prepaid expenses, deposits and other current assets 766,932  472,464  Total current assets 22,677,115  14,649,813  Property and equipment, net 174,133  252,366  Intangible asset 8,639,000  8,639,000  Right of use asset 174,668  247,043  Other assets 252,057  322,301  Total assets$31,916,973 $24,110,523  Liabilities and Stockholders’ Equity   Current liabilities:   Accounts payable$1,411,717 $1,251,412  Accrued expenses and other current liabilities 1,162,278  358,532  Current operating lease liability 112,953  111,477  Total current liabilities 2,686,948  1,721,421  Deferred income taxes 443,893  2,119,274  Noncurrent operating lease liability 61,715  135,566  Total liabilities 3,192,556  3,976,261  Stockholders’ Equity:   Common stock, $0.001 par value:   1,000,000,000 shares authorized; 64,015,441 and 33,480,365 issued and outstanding at September 30, 2020 and December 31, 2019, respectively 64,016  33,481  Additional paid-in capital 130,507,728  111,824,859  Accumulated deficit (101,847,327) (91,724,078) Total stockholders' equity 28,724,417  20,134,262  Total liabilities and stockholders' equity$31,916,973 $24,110,523      Diffusion Pharmaceuticals Inc. Consolidated Statement of Operations (unaudited)           Three Months Ended September 30, Nine Months Ended September 30,   2020  2019  2020  2019 Operating expenses:        Research and development$3,137,553  $1,743,494  $6,845,203  $4,961,720  General and administrative 2,112,375   1,290,371   4,964,440   3,559,551  Depreciation 24,192   18,178   78,233   70,840  Loss from operations (5,274,120)  (3,052,043)  (11,887,876)  (8,592,111) Other income:        Interest income 29,233   21,991   89,246   59,596  Loss from operations before income tax benefit (5,244,887)  (3,030,052)  (11,798,630)  (8,532,515) Income tax benefit 805,676   225,960   1,675,381   485,216  Net loss$(4,439,211) $(2,804,092) $(10,123,249) $(8,047,299) Deemed dividend arising from warrant exchange —   —   (1,950,378)  —  Net loss attributable to common stockholders$(4,439,211) $(2,804,092) $(12,073,627) $(8,047,299) Per share information:        Net loss per share of common stock, basic and diluted$(0.07) $(0.60) $(0.24) $(2.01) Weighted average shares outstanding, basic and diluted 64,011,342   4,693,290   50,216,239   4,005,919
GlobeNewswire · 11/12 21:02
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) ("Diffusion" or "the Company"), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusion's Chief Executive Officer.
GlobeNewswire · 10/19 12:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DFFN. Analyze the recent business situations of Diffusion Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DFFN stock price target is 2.750 with a high estimate of 3.500 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 5.88M
% Owned: 9.19%
Shares Outstanding: 64.02M
TypeInstitutionsShares
Increased
5
72.98K
New
16
-1.76K
Decreased
6
321.26K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DFFN
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Diffusion Pharmaceuticals Inc stock information, including NASDAQ:DFFN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFFN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DFFN stock methods without spending real money on the virtual paper trading platform.